HLA-A*02:01-restricted TAAs and the MiHA included in this study
| Protein . | Peptide . | Peptide binding affinity for HLA-A*02:01, nM . |
|---|---|---|
| TAA | ||
| WT1 | RMFPNAPYL | 7.14 (SB) |
| RHAMM | ILSLELMKL | 160.52 (WB) |
| Proteinase-3 | VLQELNVTV | 12.33 (SB) |
| PRAME | VLDGLDVLL | 51.09 (WB) |
| NY-eso-1 | SLLMWITQV | 6.13 (WB) |
| MiHA | ||
| HA-1 | VLHDDLLEA | 28.61 (SB) |
| Protein . | Peptide . | Peptide binding affinity for HLA-A*02:01, nM . |
|---|---|---|
| TAA | ||
| WT1 | RMFPNAPYL | 7.14 (SB) |
| RHAMM | ILSLELMKL | 160.52 (WB) |
| Proteinase-3 | VLQELNVTV | 12.33 (SB) |
| PRAME | VLDGLDVLL | 51.09 (WB) |
| NY-eso-1 | SLLMWITQV | 6.13 (WB) |
| MiHA | ||
| HA-1 | VLHDDLLEA | 28.61 (SB) |
MHC I-Streptamers for isolation and tetramers for flow cytometry analysis were available for the indicated peptides. Peptide-binding affinities for HLA-A*02:01 were predicted by using NetMHC Version 4.0. SB are predicted strong binders, and WB are predicted weak binders.